Antineoplastic agents (A61P35)

A   Human necessities(304962)
A61P35                 Antineoplastic agents(3286)
A61P35/02 - Specific for leukemia(96)
A61P35/04 - Specific for metastasis(101)

Immunity-inducing means // 2614386
FIELD: biotechnology.SUBSTANCE: invention refers to production of means containing at least one polypeptide selected from SEQ ID NO: 4, 2, 8, 10 and 12, and/or recombinant vector(s), comprising polynucleotide(s) encoding at least one polypeptide, as the active ingredient(s), and can be used in medicine. The resulting means is used for efficient induction of T-cell immunity against malignancies expressing KATNAL1.EFFECT: invention allows to obtain antigen-presenting cells presenting the polypeptide obtained from KATNAL1, and to effectively induce cytotoxic cells against KATNAL1, which is efficient as a therapeutic agent against malignant neoplasms expressing KATNAL1.7 cl, 3 dwg, 3 ex

Agent with antitumor activity based on arabinogalactan nanocomposites with selenium and methods for prepariation of such nanobiocomposites // 2614363
FIELD: pharmacy.SUBSTANCE: method of agent production includes interation of raw arabinogalactan and selenium dioxide or selenious acid salt in a solvent followed by precipitation in ethanol or acetone, or other organic solvent capable of mixing with water. The peculiarity of this method is that the process is carried out at the temperature of 20-25°C, stable selenium nanoparticles size is 0.5-250 nm, and raw arabinogalactan or arabinogalactan specially purified from phenolic impurities is used as the raw materila, while water or dimethylsulfoxide, or formamide are used as solvents.EFFECT: soluble stable nanocomposites providing antitumor activity, in dry form.3 cl, 7 dwg, 11 ex

Conjugated protein-active agents and methods of their production // 2613906
FIELD: pharmacy.SUBSTANCE: conjugated protein active agent has an amino acid motif which can be recognized via isoprenoid transferase, wherein the active agent is covalently bound via at least one linker with izosubstrate, where the izosubstrat contains at least one isoprene unit and is a recognizable isoprenoid transferase, which is attached to a cysteine residue of the amino acid motif. The invention also relates to a composition comprising conjugates, and to methods for preparing conjugates and compositions.EFFECT: use of the conjugates for the delivery of the active agent into target cells with a high selectivity.16 cl, 27 dwg, 5 ex
ethod for preoperative treatment of patients with locally advanced cervical cancer at t1b2-t2b stage // 2613888
FIELD: medicine.SUBSTANCE: invention can be used to pre-treat T1b2-T2b locally advanced cervical cancer (CC). The method comprises superselective chemoembolization of cervical arteries. Then the ascending branches of uterine arteries are cut off from the blood flow by their redistributive embolization using a hemostatic sponge. Then uterine artery chemoembolization is performed, when the superselective chemoembolization of cervical arterial and chemoembolization of uterine arteries uses 25 mg of drug-saturable HepaSpheres microspheres with dry particle size of 50-100 microns, which is saturated with 100 mg of oxaliplatin diluted in a non-ionic contrast agent.EFFECT: use of the invention can improve the efficiency of drug-saturable microspheres delivery to the cervical tumor, which reduces the risk of damage to adjacent organs and tissues and prevents the development of ischemia and necrosis.4 dwg, 2 ex
ethod for cancer adoptive immunotherapy // 2613884
FIELD: medicine.SUBSTANCE: tumor cells culture is contacted with natural killer cells and cytotoxic T-cells isolated from peripheral blood using 8 CD Micro Beads, human CD 56 and Micro Beads, human reagents. They are saturated with deuterium by incubation and culturing in the presence of interleukin-2 at a concentration of 10,000 IU/ml and heavy water concentration 7.7% at 37°C for 72 hours. Application of this method allows to increase the cytotoxic activity of lymphocytes responsible for tumor immunity, by deuterium saturation resulting in release of more stable oxidizing agents in an antitumor response.EFFECT: increased cytotoxic activity of lymphocytes in vitro.
ethod for alternative treatment of insulin-producing pancreas benign tumour // 2613717
FIELD: medicine.SUBSTANCE: for an alternative treatment of insulin-producing pancreas benign tumour, a research of immunoreactive insulin and C-peptide level is conducted. If the parameters exceed their reference values, tumour location is identified, and tumour radiofrequency thermoablation is performed with hormonal parameters monitoring. Preliminary medical therapy by 0.1 mg of octreotide injected subcutaneously 1 time per day is performed for 3 days prior to radiofrequency thermoablation. Radiofrequency thermoablation is carried out in two stages. At the first stage, radiofrequency thermoablation of the central part of the localized tumour is performed for 3 minutes at a temperature of 85-100 degrees Celsius and power 70-90 Wt under intraoperative ultrasonography supervision. The exposure is carried out at RF electrode conductors introduced to a depth of 0.4-0.7 cm . At the second stage, repeated RF thermoablation of the entire tumour within the boundaries of its detected contouris is performed with the same modes of time, temperature and power.EFFECT: persistent therapeutic effect due to minimally invasive organ-saving and almost complete destruction of tumour at low risk of intra- and postoperative complications, normalization of hormonal status.5 tbl, 5 ex
Pharmaceutical composition based on palladium compound // 2613305
FIELD: pharmacy.SUBSTANCE: invention relates to a pharmaceutical composition based on a palladium compound. The composition comprises palladium acidocomplexe of the formula: (C5H12NO)2[PDCI4] at a concentration of 0.2% in 0.9% sodium chloride aqueous solution.EFFECT: antitumor and antimetastatic action at course parenteral administration of effective doses.5 cl, 13 tbl, 6 ex
Agent increasing anti-metastatic activity of cyclophosphan // 2613189
FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to the pharmaceutical industry, particularly, to the agent increasing the anti-metastatic activity of cyclophosphan. Approximately 70% of the alcoholic extract from the aerial part of the meadowsweet (Filipendula ulmaria (L.) Maxim.) as the agent increasing the anti-metastatic activity of cyclophosphan.EFFECT: agent effectively increasing the anti-metastatic activity of cyclophosphan.2 tbl, 2 ex
Gelatine capsule of selective vessel destruction in tumours // 2613146
FIELD: medicine.SUBSTANCE: gelatine capsule of selective vessel destruction in tumours relates to field of pharmaceutics and medicine, in particular to oncology, and deals with novel medications, mechanism of action of which consists in their destruction of already existing vessels inside tumour, preventing in such way supply of blood and oxygen, vital for survival of solid tumours with dimensions exceeding 1 mm. The capsule contains approximately 250-900 mg of pharmaceutical composition, which contains anti-tumour compound 7-methoxy-4-nitro-3-(p-methoxyphenyl)isoquinolinone 16-18 wt %, crospovidone 5-8 wt %, hypromellose 2-3 wt %, polysorbate 80 - 1-2 wt %, sodium laurylsulphate 0.7-1.2 wt %, the remaining part - mannitol, in gelatine capsule.EFFECT: invention solves the task of creating novel peroral anti-tumour medication for prevention or treatment of benign or malignant tumours, independently on their origin or size, within the framework of treating mammals, in particular humans, resistant to traditional treatment.3 cl, 1 tbl
ethod of producing drug and drug preparation // 2613106
FIELD: medicine.SUBSTANCE: invention relates to medicine and pharmaceutical chemistry, particularly it concerns drug, based on nanoparticles of phthalocyanine, which can be used in treating malignant new growths by pulsed laser ablation of nanoparticles. Three-stage method of producing drug is described and thus produced preparation with following composition in wt%: phthalocyanine in form of nanoparticles 0.1–1.0; SAS 0.1–1.5; sodium chloride 0.1–1.5; water – rest.EFFECT: drug preparation, produced by this method, shows high efficacy, providing tumor growth inhibition (TGI) up to 100 %, as well as stability during storage – after 3 years storage size of phthalocyanine nanoparticles changed insignificantly.3 cl, 2 tbl, 7 ex
Selective protein kinase inhibitors // 2612972
FIELD: chemistry.SUBSTANCE: invention relates to a compound of formula I or a pharmaceutically acceptable salt thereof, where R1 is hydrogen or (C1-C10)alkyl group; R2 is H, halogen, COOH, (C1-C6)alkyl, optionally substituted with -NR10R11, OH or (C1-C4)alkoxy, optionally substituted OH; (C1-C6)alkoxy, optionally substituted OH, (C1-C4)alkoxy or group -NR12R13; group of -OR14, where R14 denotes a 5- or 6-member heterocycloalkyl, containing 1 or 2 nitrogen atoms; group -CONR15R16, where R15 and R16 each independently denotes H or (C1-C4)alkyl, optionally substituted (C1-C4)alkoxy or 5- or 6-member heterocycloalkyl, containing 1 or 2 heteroatoms selected from O and N; group -NR17R18, where R17 denotes H or (C1-C4)alkyl and R18 denotes H, (C1-C4)alkyl, optionally substituted with (C1-C4)alkoxy, or 5- or 6-member heteroaryl containing 1–3 heteroatoms selected from O, S and N; group -NR19COR20, where R19 denotes H and R20 denotes (C1-C4)alkyl, optionally substituted amino, (C1-C4)alkylamino or di(C1-C4)alkylamino or 5- or 6-member heterocycloalkyl, containing 1 or 2 nitrogen atoms, said heterocycloalkyl is optionally substituted with 1–3 (C1-C4)alkyls; or 5- or 6-member heterocycloalkyl or heteroaryl containing 1 or 2 nitrogen atoms, said heterocycloalkyl or heteroaryl is optionally substituted with oxo groups; R3 is hydrogen, halogen, cyano, (C1-C10)alkyl group or (C1-C10)alkoxy group, CF3; Q denotes O or S; W is N or CR21; X is N or CR25, where R25 is H; CN; (C1-C4)alkyl; or group -COO(C1-C4)alkyl; and A denotes a 5- or 6-member heterocycloalkyl or heteroaryl containing 1–3 nitrogen atoms, said heterocycloalkyl or heteroaryl is optionally substituted with 1–3 substitutes, selected from an oxo group; halogen; (C1-C4)alkyl, optionally substituted amino, (C1-C4)alkylamino, di(C1-C4)alkylamino or 5- or 6-member heterocycloalkyl, containing 1 or 2 nitrogen atoms. Invention also relates to a pharmaceutical composition for treating a disease mediated by inhibition of native and/or mutant c-kit, containing a compound of formula I or its pharmaceutically acceptable salt and at least one pharmaceutically acceptable carrier.EFFECT: selective inhibitors of native and/or mutant protein kinase c-kit.10 cl, 3 tbl, 225 ex
2-pyridyl substituted imidazoles as alk5 and/or alk4 inhibitors // 2612958
FIELD: chemistry.SUBSTANCE: invention relates to organic chemistry, specifically to a novel 2-pyridyl-substituted imidazole derivative of formula (I), where R1 is phenyl, pyridyl or thienyl, condensed with a structural fragment, which together with two ring members of said phenyl, pyridyl or thienyl forms a 5-6-member aromatic or non-aromatic saturated ring, wherein said ring optionally contains up to two heteroatoms, independently selected from O, N and S, and condensed phenyl ring is optionally substituted with one group, independently selected from halogen, -O-C-1-6alkyl, -C1-6alkyl, -O-(CH2)q-NR4R5, or 5-member heteroaryl containing up to two heteroatoms, independently selected from N; or R1 is phenyl, substituted with one or more groups, independently selected from halogen, -O-C1-6alkyl, -S-C1-6alkyl, -C1-6alkyl, -C1haloalkyl, -CN, -(CH2)p-NR4R5, -(CH2)p-NHCOR4, -(CH2)p-NHCO2R4; -(CH2)p-NHSO2R4 or N-bound 6-member heterocycle, where said heterocycle comprises two heteroatoms, independently selected from O, N, and optionally substituted with C1-6alkyl; R2 is -C1-6alkyl; R3 is H, -(CH2)p-NR4R5, -(CH2)p-CN, -(CH2)p-CO2R4, -(CH2)p-CONR4R5, -(CH2)p-OR4, -(CH2)p-NHCOR4; R4 and R5 independently denote H or -C1-6alkyl; p denotes an integer ranging from 0 to 1; q denotes 2; n denotes an integer ranging from 1 to 2; X is NR7; and R7 is H or -CO-C1-6alkyl. Invention also relates to use of a compound of formula (I), a pharmaceutical composition based on compound of formula (I) and to a method of preventing or treating diseases, based on use of compound of formula (I).EFFECT: technical result is obtaining novel heterocyclic compounds effective in treating or preventing a disease, mediated by ALK5 and/or ALK4 receptors in a mammal.8 cl, 44 ex, 1 tbl

phosph1 peptides and vaccines containing them // 2612905
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology, namely to anti-tumor vaccines based on epitope peptides MPHOSPH1 and can be used in medicine. Peptide is obtained consisting of amino acid sequence SEQ ID NO: 120. Peptide can contain replacement of C- and/or N-terminal amino acid of above sequence to leucine or methionine. Obtained epitope peptide has ability to induce cytotoxic T-lymphocytes (CTL) in presence of antigen presenting cell (APC) carrying HLA-A*0201 or HLA-A*0206.EFFECT: invention allows inducing immune response against malignant tumor expressing MPHOSPH1 in individual, HLA antigen of which is HLA-A*0201 or HLA-A*0206.14 cl, 6 dwg, 3 tbl, 1 ex

Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof // 2612788
FIELD: medicine.SUBSTANCE: present invention relates to gene therapy for treating eye diseases, more specifically to use vectors for conditional expression of one or more therapeutic protein under the control of gene expression modulation system in the presence of activating ligand in the preparing of a drug, and can be used in medicine.EFFECT: present invention allows to engineer a conditional expression vectors, which can be used for treating macular degeneration or glaucoma in an individual.10 cl, 40 dwg, 8 tbl, 12 ex
Dispiropyrrolidine derivatives // 2612534
FIELD: chemistry.SUBSTANCE: invention relates to a dispiropyrrolidine derivative of general formula (1), where ring A is a spiro compound 4-6-member saturated hydrocarbon ring, which can contain one or more substitutes, ring B is a benzene ring which can contain one or more substitutes, or a pyridine ring, which can contain one or more substitutes, R1 is an aryl group which can contain one or more substitutes, or heteroaryl group, which can contain one or more substitutes, R2 is a hydrogen atom; and R3 is a group presented by general formulae (2), (3) or (4), which inhibits protein interaction between Mdm2 and p53 protein and has antitumour activity.EFFECT: dispiropyrrolidine derivatives are disclosed.29 cl, 199 ex R3 :

Phenyl-guanidine derivatives // 2612533
FIELD: chemistry.SUBSTANCE: invention relates to use of a compound of formula (I) or a pharmaceutically acceptable salt thereof, or any of stereoisomeric forms thereof, or mixtures thereof for treating pathological condition mediated by Rac1 cell proteins. In formula (I) R1 and R1' are independently selected from a group consisting of H and CF3 (provided that at least one of R1 and R1' is different from H); A is a carboxylic or heterocyclic ring system with one ring, where ring forming ring system, contains 5–7 members, where each member is independently selected from C, N and CH; or denotes an aromatic ring; wherein A substituted with one or more radicals selected from a group consisting of H, nitro, straight or branched (C1-C6)alkyl, halogen-(C1-C6)alkyl and -SO2NR3R4; where each R3 independently represents H or straight or branched (C1-C4)alkyl, each R4 independently represents H or straight or branched (C1-C6)alkyl. Invention also relates to a compound of formula (II), method for production thereof and pharmaceutical composition containing said compound. In formula (II) A is a carboxylic or heterocyclic ring system with one ring, where ring forming a ring system contains 5–7 members, where each member is independently selected from C, N and CH; or denotes an aromatic ring.EFFECT: disclosed compounds can be used as agents for treating fast-growing and/or resistant tumours.14 cl, 9 dwg, 3 tbl, 7 ex (I) (II)

Novel prodrugs of nucleic acids and their application methods // 2612521
FIELD: medicine.SUBSTANCE: invention relates to applicable in medicine oligonucleotides of formula 1: ,where R1 is -OH or -SH; R2 represents H, -OH or -ORb, where Rb is locking group, which temporarily masks reactivity of functional group and can be removed; Ba is adenine, cytosine, 5-methylcytosine, guanine, thymine or uracil; fragment X is selected from -OCH2CH2S-S(O)2R10, -OCH2CH2S-SCH2CH2OH, -OCH2CH2CO2H, , , , , , , , , ,, , , , , и ,R10 is C1-4 alkyl; R11 is C1-10 alkyl or C3-10 cycloalkyl; R12 is H or C1-10 alkyl; R3 is H; n equals integer number from 10 to 200; and X-phosphonate fragment in each case independently is formed with more than 98 % of diastereomeric purity according to 31P NMR spectroscopy or reverse-phase HPLC.EFFECT: novel oligonucleotide is proposed promising for treating cancer.7 cl, 4 dwg, 2 tbl, 395 ex

eans for prevention and treatment of benign prostatic hyperplasia // 2612268
FIELD: medicine.SUBSTANCE: means relates to medicine and is intended for prevention and treatment of benign prostatic hyperplasia. For benign prostatic hyperplasia prevention and treatment, 4-hydroxymethyl-2,6-diisobornylphenol dosed as 10 mg/kg of body weight is used.EFFECT: increased efficiency of benign prostatic hyperplasia prevention and treatment.9 dwg, 1 ex
Dioxino- and oxazin-[2,3-d]pyrimidine compounds as phosphoinositide 3-kinase inhibitors and methods for use thereof // 2612251
FIELD: chemistry.SUBSTANCE: invention relates to a compound of formula I , which are used as inhibitors of phosphoinositide 3-kinase (PI3-kinase), having anticancer activity, anti-inflammatory activity or immunoregulatory properties.EFFECT: technical result is obtaining novel compounds of formula I, as well as pharmaceutical compositions based thereon, which can be used for producing a drug for treating cancer, in particular, cerebral cancer.23 cl, 1 tbl, 41 ex
ethod of personalized intra-arterial chemotherapeutic agent infusion during treatment of squamous cell carcinoma of head and neck // 2612095
FIELD: medicine.SUBSTANCE: dominant vessel supplying the tumour is identified. Its selective catheterization is performed, and volumetric blood flow rate is determined. Platinum drug is administered at a rate equal to or exceeding the volumetric blood flow rate by max. 16.7%. The administered drug volume is calculated from the ratio of 75-100 mg/m2 of the patient body surface area. Then, 5-fluorouracil is administered in the same vessel, at an infusion rate equal to or exceeding the vessel volumetric blood flow rate by max. 16.7% in a volume of 250 ml.EFFECT: method can reduce the severity of toxic reactions to chemotherapy, eliminate complications and deaths related to the treatment itself, eliminate the pathological changes in kidney function and improve the overall one-year survival rates to 94 percent.
ethod for treatment of locally spread unresectable esophageal cancer // 2612090
FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to oncology, and can be applied for treatment of locally spread unresectable esophageal cancer. For this purpose in conditions of procedure room after processing chest skin with antiseptic solution patients receive intradermally by 0.3 ml of autologous dendritic-cell vaccine, two injections from each side of chest approximately between III and IV, IV and V ribs. Dose constitutes 5,000,000 dendritic cells. 2 weeks after introduction of first vaccine second dendritic-cell vaccine is introduced in the same dose. 2 weeks after introduction of second vaccine third dendritic-cell vaccine is introduced in total dose 10,000,000 dendritic cells. 2 weeks after third introduction of vaccine fourth dendritic-cell vaccine is introduced in total dose 10,000,000 dendritic cells. During the entire course of vaccine therapy patients receive 30,000,000 cells.EFFECT: invention makes it possible to increase duration and to improve quality of life in patients with locally spread unresectable esophageal cancer.1 ex
Peptide-immunogen used in therapeutic vaccine for treatment of metastatic breast cancer of cats and dogs // 2612015
FIELD: medicine, veterinary medicine.SUBSTANCE: peptide immunogen with the following amino acid sequence is used: CKGPIVLDGVIKTQPHAAEK (SEQ ID NO: 1), identical to the amino acid sequence of the active center of EGFR receptor of cats and dogs. To enhance the immune response, the peptide comprises covalently linked carrier protein. It contains bovine serum albumin (BSA) or cationized bovine serum albumin, or ovalbumin or hemocyanin as a carrier protein.EFFECT: application of the peptide allows to form endogenous antibodies of narrow specificity in animal bodies, that are directed specifically to functionally significant areas of the tumour cells receptor, and to block the main paths of tumour growth and metastasis due to the high peptide immunogenicity and ensured formation of immune response to the protective epitopes of targeted tumour markers only.2 cl, 1 tbl, 1 dwg
Silver nanocomposite based on arabinogalactan conjugate and flavonoids with antimicrobial and antitumor action and preparation method thereof // 2611999
FIELD: medicine.SUBSTANCE: invention is zero valent silver nanocomposite with both antimicrobial and antitumor action in the form of stable water-soluble powder that preserves its properties over a long time, containing natural arabinogalactan bioconjugate with flavonoids, with silver nanoparticles size of 1.7-90.0 nm and their content in the composite equal to 1.3-17.5%, as nanoparticle stabilizer. The invention also relates to a method for preparation of zero-valent silver nanocomposite.EFFECT: preparation simplicity, preservation of the natural structure of arabinogalactan, application of neutral pH and room temperature during preparation, nanocomposite stability, simultaneous antimicrobial and antitumor action.2 cl, 6 ex, 2 tbl, 1 dwg
ethod for photodynamic therapy of surface cancer and precancerous conditions of penis // 2611952
FIELD: medicine, pharmacy.SUBSTANCE: invention refers to medicine, namely to urology and oncology. Intravenous injection of "Photoditazine" photosensitizer doses of 0.8-1.2 mg/kg of body weight is performed. In 2 hours after injection, the pathologic nidus is exposed to laser radiation with a wavelength of 662 nm. The power density is 200-400 mW/cm2. Irradiation is carried out by fractions with total radiation dose of 250 J/cm2. An irradiation session is divided into two equal portions at intervals of 20-30 minutes. The method allows to increase the efficiency of treatment, maintain anatomical and functional integrity of the body with a good cosmetic effect due to 2 stages of an irradiation session, which ensures prevention of photosensitizer burnout; the first fraction of irradiation provides photodynamic destruction of tumor cells, the second fraction - the destruction of organ blood flow.EFFECT: invention can be used for photodynamic therapy of surface cancer and precancerous conditions of penis.2 ex
Composition for imaging and damaging of target cells // 2611653
FIELD: pharmaceutics.SUBSTANCE: invention relates to pharmaceutical industry, namely to composition for imaging and damaging of tumor cells, containing inorganic nanoparticles with size of 10–100 nm and dimensional dispersity of up to 6% of NaYF4, co-alloyed with ions of ytterbium (Yb) and erbium (Er) or ytterbium (Yb) and thulium (Tm), and including cytotoxic component represented by beta-isotope, which is isotope yttrium-90 (90Y), nanoparticles are transferred into hydrophilic state by using coating of at least one of compounds selected from polymaleic anhydride of octadecene, polyethyleneimine, poly(D,L-lactide), poly(lactide-glycolide), silicon dioxide, tetramethylammonium hydroxide, wherein nanoparticles are linked with humanized mini-antibody scFv 4D5 or high affinity peptide of non-immunoglobulin nature DARPin-29, which are specific to cancer associated antigen HER-2/new.EFFECT: invention provides possibility of local directed therapeutic effect due to damaging action of beta-radiation simultaneously with possibility of optical visualization of pathological center with lower risk of poisoning of nearby tissues.1 cl, 6 dwg
Arylcyclopropylamine based demethylase inhibitors of lsd1 and their medical use // 2611437
FIELD: chemistry; pharmaceutics.SUBSTANCE: invention relates to novel compounds of formula (I) or its pharmaceutically acceptable salt or solvate, which have inhibiting activity lysine specific demethylase-1 (LSD1). In compounds of formula (I) (A) means phenyl or pyridyl, where said phenyl or pyridyl comprises n substitutes (R3); (B) means -O-CH2-phenyl or phenyl, where said phenyl or phenyl fragment, contained in the above -O-CH2-phenyl, comprises n substitutes (R2); (D) means a monocyclic heteroaryl group containing 5 or 6 ring members, where one to three said ring members are heteroatoms, selected from O, S and N, where said heteroaryl group contains one substitute (R1) and, besides, where said heteroaryl group is covalently bonded to molecules through circular carbon atom; (R1) means -NH2; each (R2) is independently selected from a group comprising C1-C6alkyl, hydroxy group, halogen, C1-C6haloalkyl, C1-C6haloalkyl oxy group or C1-C6alkoxy group; each (R3) is independently selected from a group comprising C1-C6alkyl, a hydroxy group, halogen, C1-C6haloalkyl, C1-C6haloalkyl oxy group or C1-C6alkoxy group; and n independently equal to 0, 1, 2 or 3.EFFECT: compounds can be used for treatment or preventing cancer, selected from a prostate cancer, breast cancer, lung cancer, colorectal cancer, cerebral cancer, blood cancer or leukemia; neurological diseases, including depression, Alzheimer's disease, Huntington's disease, Parkinson's Disease, amyotrophic lateral sclerosis, frontal-temporal dementia or dementia with Lewy bodies; or viral infection caused by herpes virus, or selected from a group of HSV-1, HSV-2, and Epstein-Barr virus.66 cl, 2 tbl, 38 ex
Preparation for application in photon capture therapy of malignant solid neoplasms // 2611379
FIELD: medicine; pharmacology.SUBSTANCE: preparation for application in photon capture therapy of malignant solid neoplasms represents pharmaceutical substance, which composition of which includes diethylenetriaminopentaacetic acid in form of its disodium salt, characterised by the fact that as pharmaceutical composition used is complex of bismuth with diethylenetriaminopentaacetic acid (H5dtpa) in form of its disodium salt BiNa2dtpa with general formula and in the following weight ratio: BiNa2dtpa (BiNa2C14H18O10N3) 305.0-330.0 mg; diethylenetriaminopentaacetic acid (H5dtpa) 0.1 mg, or 0.2 mg, or 0.3 mg.EFFECT: improvement of properties.2 cl, 2 ex, 7 tbl
Water-soluble composition, possessing anti-tumour activity and method for obtaining thereof // 2611362
FIELD: medicine.SUBSTANCE: composition contains, wt %: soloxolon methyl 4.0-40.0; PEG with molecular weight 4000 Da - 40.0-57.4; β-glycine - 10.0-56.0. The invention also deals with method for obtaining composition, the method includes dissolution of soloxolon methyl and PEG in tert-butyl alcohol with ultrasonic impact and simultaneous heating of mixture to 45-50°C for 5-30 minutes until components are completely dissolved, after that addition of β-glycine and re-exposure of mixture to ulrrasound for 7-10 min, freezing and exposure of the obtained suspension at temperature -20°C for 4 hours, with the following lyophilic drying first at temperature -20°C until pressure in chamber drops lower than 17 mtorr, then at temperature 30°C for 2 hours.EFFECT: increase of water-solubility and anti-tumour activity of composition.2 cl, 3 dwg, 2 tbl, 7 ex

Pharmaceutical composition for cancer treatment and/or prevention // 2611197
FIELD: medicine, pharmacy.SUBSTANCE: invention relates to biochemistry, namely to an antibody or fragment thereof, wherein the antibody or fragment thereof specifically binds to CAPRIN-1 protein, DNA, its encoder, as well as to a conjugate of the said antibody or fragment thereof with an antitumor agent. The invention also relates to pharmaceutical composition and pharmaceutical combination for cancer treatment or prevention, in which CAPRIN-1 is expressed on the malignant cell surface, as well as to a method for cancer treatment or prevention, in which CAPRIN-1 is expressed on the malignant cell surface using the above antibody or fragment thereof.EFFECT: invention enables efficient cancer treatment or prevention, in which CAPRIN-1 is expressed on the malignant cell surface.8 cl, 7 ex

Aprotinin polypeptides for transport of compound through blood-brain barrier // 2611193
FIELD: biotechnology.SUBSTANCE: present invention relates to biotechnology, namely to delivery of anti-cancer agents to mammal cells. Invention enables to obtain conjugate of Angiopep-2 polypeptide aprotinin with three taxol molecules, which can be used in therapy of patients suffering from cerebral cancer.EFFECT: obtained conjugate can effectively overcome blood-brain barrier in mammal and deliver drug to brain cells.3 cl, 9 dwg, 6 tbl, 3 ex
2-(azaindol-2-yl)benzimidazole derivatives as pad4 inhibitors // 2611010
FIELD: chemistry.SUBSTANCE: invention relates to organic chemistry, specifically to 2-(azaindol-2-yl)benzimidazole derivatives of formula (I) or a pharmaceutically acceptable salt thereof, where R1 is hydrogen; R2 is hydrogen, perhalomethylC0-5alkyl-O- or C1-6alkoxy; R3 is C1-6alkyl or C1-6alkoxyC1-6alkyl; R4 is C1-6alkyl, perhalomethylC1-6alkyl or unsubstituted C3cycloalkylC1-6alkyl; A is C-R5 or N; B is C-R6 or N; D is C-R7 or N; provided that one of A, B and D is N; R5, R6 and R8 are hydrogen; R7 is hydrogen, C1-6alkoxy or hydroxy; R9 is hydrogen or hydroxy; R10 is hydrogen or C1-6alkyl. Invention also relates to specific derivatives of 2-(azaindol-2-yl)benzimidazole and a pharmaceutical composition based on compound of formula (I).EFFECT: novel derivatives of 2-(azaindol-2-yl)benzimidazole, useful as PAD4 inhibitors are obtained.10 cl, 30 ex

Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)piperidine-2,6-dione derivatives and their pharmaceutical compositions and use // 2611007
FIELD: pharmaceutics.SUBSTANCE: invention relates to polymorphous solid crystalline forms 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)piperidine-2,6-dione of following structural formula. Solid crystalline forms of compound corresponding to structural formula , represent crystalline form A1 of hydrochloride salt of said compound with indications of powder x-ray peak at approximately 8.6, 13.1, 20.5 and 26.3 degrees 2θ; either crystalline form of A monohydrate of said compound, having powder x-ray, including peaks at approximately 14.6, 15.6, 16.7, 21.9 and 30.0 degrees 2θ; crystalline form B, having powder x-ray, including peaks at approximately 10.6, 14.7, 19.1 and 25.9 degrees 2θ; crystalline form C with powder x-ray, including peaks at approximately 10.8, 15.1, 25.1 and 26.6 degrees 2θ; crystalline form E hydrate with powder x-ray, including peaks at approximately 7.3, 14.6, 22.0, 30.0 and 37.0 degrees 2θ; crystalline form F, having powder x-ray, including peaks at approximately 14.5, 15.7, 22.7 and 29.9 degrees 2θ. Invention covers also data of differential scanning calorimetry, thermogravimetric analysis data, indices of hygroscopicity and stability of obtained solid crystalline forms. Invention also relates to pharmaceutical composition containing therapeutically effective amount of solid shape and pharmaceutically acceptable carrier, thinner or excipient.EFFECT: compound possesses properties of TNF-α and can be used for treating various forms of cancer, angiogenesis, macular degeneration and associated syndrome, pain and other disorders and diseases associated with TNF-α.42 cl, 23 dwg, 10 tbl, 4 ex

Antibodies to folic acid receptor 1, their immunoconjugates and application // 2610663
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology and immunology. Humanized antibody and its antigen-binding fragment are disclosed, specifically binding to human folic acid receptor 1 (FOLR1) and characterized by amino acid sequences of sections determining complementarity with antigen (CDR). Method of producing humanized antibodies under invention; immunoconjugates with cytotoxic agent; pharmaceutical composition; diagnostic composition; kits; methods of inhibiting tumor growth and method of treating cancer are also disclosed. Isolated polynucleotides coding variable domains of disclosed antibodies; vectors containing them and host cells are also disclosed.EFFECT: antibody under invention is humanized form of mouse antibody Mov19 and it can find further application in therapy of diseases characterized by high expression of FOLR1.69 cl, 19 dwg, 4 tbl, 19 ex

Pharmaceutical composition for treating and/or preventing malignant growth // 2610428
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry, namely to antibody or its fragment, which possess immune responsiveness in relation to protein CAPRIN-1. Invention also discloses antibody, which specifically binds to CAPRIN-1, pharmaceutical composition containing said antibody or its fragment or conjugate for treating or preventing malignant tumors, associated with CAPRIN-1, DNA, coding said antibody. Method of treating or preventing malignant tumors, associated with CAPRIN-1, using disclosed antibody is proposed.EFFECT: invention enables specific binding to CAPRIN-1, which enables effective treatment of malignant tumor associated with expression of CAPRIN-1.8 cl, 8 ex

Crystalline β-modification of n-(3-ethylphenyl)-6,7-bis(2 methoxyethoxy)quinazoline-4-amine hydrochloride, method for production thereof and pharmaceutical composition based thereon // 2610337
FIELD: chemistry.SUBSTANCE: invention relates to a novel crystalline modification of crystalline β-modification of N-(3-ethylphenyl)-6,7-bis(2-methoxyethoxy)quinazoline-4-amine hydrochloride (erlotinib hydrochloride). Said compound has properties of inhibitor of epidermal growth factor of tyrosine kinase receptors and can be used for treating oncological diseases. Crystalline β-modification is characterised by a set of interplanar distances (d, Å) and corresponding intensities (Irelative,%) – 22.849–27.01 %; 21.101 – 33.82 %; 19.175 – 0.41 %; 18.609 – 48.34 %; 16.707 - 100 %; 14.463 – 15.57 %; 12.358 -13.54 %; 10.869 – 11.52 %; 10.099 – 14.19 %; 9.372 – 29.03 %; 8.759 -14.52 %; 7.160 – 14.19 %; 6.958 – 12.17 %; 6.557 – 11.19 %; 6.252 – 10.46 %; 6.007 – 13.54 %; 5.865 – 14.19 %; 5.721 – 13.22 %; 5.564 – 15.25 %; 5.337 -17.60 %; 5.206 – 15.25 %; 4.925 – 14.52 %; 4.742 – 18.90 %; 4.591 – 16.87 %; 4.397 – 16.55 %; 4.300 – 19.63 %; 4.187 – 20.60 %; 3.958 – 22.95 %; 3.914 -23.36 %; 3.821 – 31.79 %; 3.717 – 29.03 %; 3.528 – 19.95 %; 3.444 – 19.63 %; 3.325 – 12.73 %; 3.215 – 10.79 %; 3.053 – 10.46 %; 2.889 – 11.19 %; 2.837 -10.79 %; 2.721 – 7.79 %; 2.607 – 5.76 %; 2.497 – 5.43 %; 2.341 – 6.08 %; 2.274 – 5.43 % and melting temperature equal to 212.4 ± 0.5 °C. Invention also relates to a method of producing said crystalline β-modification. Method comprises dissolving erlotinib hydrochloride at 40–100 °C in distilled water, acidified with 0.1 M hydrochloric acid to pH 2–4, frozen at cooling rate not less than 60 deg/min and subjected to sublimation drying.EFFECT: sublimation drying of frozen erlotinib hydrochloride solution is carried out at temperatures: on condenser (-43)–(-56) °C; on product (-196)–(+50) °C and residual pressure in chamber (9-3)×10-2 torr for 22–26 hours.4 cl, 5 dwg, 4 tbl, 4 ex

New conjugates binding compound - active compound (adc) and use thereof // 2610336
FIELD: medicine.SUBSTANCE: present invention relates to novel conjugates of binding compound – active compound of (ADC) N,N-alkylauristatins targeted against target C4.4a, active metabolites of said ADC conjugates, method of obtaining said ADC conjugates, use of said ADC conjugates for treating and/or preventing diseases, as well as use of these ADC conjugates to produce medicinal agents for treating and/or preventing diseases, more specifically hyperproliferative and/or angiogenic diseases, such as, for example, cancer.EFFECT: such drug treatment can be used in form of single agent therapy or, in another version, in combination with other drugs or additional other therapeutic measures.52 cl, 6 tbl, 128 ex
Nanomaterial for targeted delivery of anticancer agents and anticancer agents based on it // 2610170
FIELD: medicine.SUBSTANCE: group of inventions refers to the medicine, particularly, to the oncology and molecular biology, and reveals the nanomaterial for targeted delivery of an anticancer agent to a tumor localization area. The nanomaterial includes particles of magnetite covered with a hydrophilic polymer containing a vector fragment, as its constituent, able to bind to sugars on the surface of cancer cells and selected from a group of plant lectin. Additionally, an anticancer agent is proposed, which provides its targeted delivery to a cancer localization area, containing the mixture of the said nanomaterial with a cytotoxic agent.EFFECT: group of inventions allows effective delivery of cytotoxic agents to cancer cells by means of the vector fragment, viscumin, accompanied by release of the agent impacted by the external magnetic field or without it. This provides diagnostics and treatment of tumors, as well as reduction of total toxicity of cytostatic agents applied in medical practice, such as doxorubicin, paclitaxel.16 cl, 8 ex
Organic compounds // 2610094
FIELD: chemistry.SUBSTANCE: invention relates to a compound of formula IV, wherein R6 and R7 are independently halogen, -SO2NH2, -COOH or H; R2 and R5 represent H; in free form or in form of a pharmaceutically acceptable salt. Compound of formula IV binds to nicotinic acetylcholine receptor with high affinity. Invention also relates to a pharmaceutical composition and method of treating, or preventing a disease or disorder, characterised by activation of acetylcholine receptor pathway.EFFECT: for example, compounds and methods of treating function as blocking activity of certain acetylcholine receptors and their subtypes and are used to treat diseases and conditions mediated by irritation of nicotinic receptors, for example small cell lung cancer, symptoms of cognitive impairment, such as Alzheimer's disease.26 cl, 2 tbl, 13 ex
Dosage forms of histone deacetylase inhibitor in combination with bendamustine and their application // 2609833
FIELD: medicine, pharmacy.SUBSTANCE: group of inventions refers to pharmacy. A combination for cancer treatment, comprising bendamustine or pharmaceutically acceptable salt thereof and an HDAC inhibitor. Compound 1, or pharmaceutically acceptable salt thereof is used as the HDAC inhibitor. Application of the said composition for cancer treatment is also described.EFFECT: invention provides implementation of the specified purpose (compound 1).10 cl, 13 dwg, 17 ex, 13 tbl

Prostate-associated antigens and immunotherapy schemes based on vaccines // 2609651
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology, specifically to obtaining multi- antigen DNA constructs, expression vectors, containing said constructs, and pharmaceutical compositions, that can be used in medicine. Multi- antigen DNA constructs are obtained for expression of the immunogenic polypeptides of prostate-specific antigens PSA, PSCA, PSMA, that is used in a composition for inhibiting the abnormal cell proliferation or inducing an immune response against prostate-associated antigen in mammals.EFFECT: invention allows with high efficiency to treat prostate cancer in humans.24 cl, 43 dwg, 33 tbl, 20 ex

Block of ccl18 signaling through ccr6 as therapeutic method of treating fibrotic diseases and cancer // 2609649
FIELD: biotechnology.SUBSTANCE: invention relates to biotechnology, namely to use of soluble polypeptide of CCR6 receptor in treating of interstitial pulmonary disease and/or lung cancer. Polypeptide containing CCLVYTSWQI, which consists of amino acid sequence, which has at least 90 % identity with respect to sequence according to SEQ ID NO: 9. Its fragment is also obtained, containing at least 12 amino acids of above sequence, including CCLVYTSWQI.EFFECT: invention allows preparing polypeptide capable to inhibit CCL18 induced step-down regulation of CCR6 expression.1 cl, 33 dwg, 17 ex

Anti-cd40-antibodies and methods of application // 2609647
FIELD: medicine, pharmacy.SUBSTANCE: invention refers to biochemistry. An isolated antibody or antigen-binding fragment that is bound to human CD40 and acts as agonists of CD40 is described. An isolated polynucleotide encoding an isolated antibody or antigen-binding fragment thereof, an expression vector containing an isolated polynucleotide isolated host cell to produce an antibody or antigen-binding fragment thereof are described. A composition for treatment or alleviation of a disease or disorder associated with CD40, comprising a physiologically acceptable carrier and a therapeutically effective amount of the isolated antibody or antigen-binding fragment thereof is presented. Methods for treatment or alleviation of symptoms for patients having cancer, reduction of symptoms for patients having autoimmune diseases, alleviation of symptoms for patients having inflammatory diseases, including composition injection are presented.EFFECT: invention increases the variety of CD40 antagonists.29 cl, 18 dwg, 1 tbl, 3 ex
Selective glycosidase inhibitors and use thereof // 2609210
FIELD: chemistry.SUBSTANCE: invention relates to compounds of formulae (1), (2) or (3), or pharmaceutically acceptable salt thereof. Invention also relates to a pharmaceutical composition containing as an active ingredient a compound of formulae (1), (2) or (3), having inhibitory action on O-GlcNAcase, or a pharmaceutically acceptable salt thereof and pharmaceutically acceptable carrier. Compounds or pharmaceutically acceptable salt thereof are intended for treating Alzheimer's disease, Parkinson's disease or progressive supranuclear palsy (PSP) in a human patient in need thereof.EFFECT: technical result is compounds which are selective inhibitors of glycosidase.45 cl, 6 tbl, 33 ex (1), (2), (3).
orpholino-substituted derivatives of bicyclic pyrimidine urea or carbamate as mtor inhibitors // 2609208
FIELD: pharmaceutics.SUBSTANCE: invention relates to compounds of formula (I) and their pharmaceutically acceptable salts . In formula (I) m is equal to 1; o equals 1 or 2; each R1 is independently selected from group consisting of H and unsubstituted C1-6alkyl; two R1 are possibly combined to form, together with ring, to which they are bonded, 8-oxa-3-azabicyclo[3.2.1]octane-3-yl or 3-oxa-8-azabicyclo[3.2.1]octane-8-yl ring; T1 is phenyl, where T1 is substituted by group N(R5a)C(O)N(R5bR5) and T1 is optionally additionally substituted with one or more R6, which are identical or different; R6 is halogen; each of R5a, R5b represents H; R5 represents H; T2; and C1-6alkyl, where C1-6alkyl is optionally substituted with one or more R8, which are identical or different; R8 represents halogen or OR9; R9 represents H; T2 is unsubstituted and selected from group consisting of phenyl, pyridyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, oxetanyl or tetrahydrofuranyl; Ra and Rb are selected to obtain one of formulae (Ik)–(Ip) or Ra, Rb, T1 are selected to obtain formula (Iq) R14, R14a, R14b, R14c are independently selected from group consisting of H; halogen or unsubstituted C1-6alkyl. Compounds of formula (I) possess mTOR inhibiting activity. Invention also relates to pharmaceutical composition containing compounds of formula (I), use of compounds for making drug and to method of treating.EFFECT: novel compounds of formula (I) are obtained, which have mTOR inhibitor activity, which can be used for treating or preventing mTOR related diseases and disorders.16 cl, 15 tbl, 82 ex

Compounds for treating cancer // 2609018
FIELD: chemistry.SUBSTANCE: invention relates to a compound of structural formula (XI), where X is NH; Q is NH or S; and A is a substituted or unsubstituted furanyl, indolyl, phenyl, biphenyl, triphenyl, diphenylmethane, thiophenyl, adamantanyl or fluorenyl; wherein said ring A is optionally substituted with 1-5 substituents, which are independently O-alkyl, O-haloalkyl, F, Cl, Br, I, haloalkyl, CF3, CN, -CH2CN, NH2, hydroxyl, -(CH2)iNHCH3, -(CH2)iNH2, -(CH2)iN(CH3)2, -OC(O)CF3, C1-C5 straight or branched alkyl, haloalkyl, alkylamino, aminoalkyl, -OCH2Ph, -NHCO-alkyl, COOH, -C(O)Ph, C(O)O-alkyl, C(O)H, -C(O)NH2 or NO2; and i is an integer from 0 to 5. Compound of formula (XI) can be in form of an isomer, pharmaceutically acceptable salt thereof, tautomer or hydrate. Invention also relates to a pharmaceutical composition for treating cancerous diseases, containing said compound and pharmaceutically acceptable carrier. Compound of formula (XI) is intended for treatment, suppression, reducing degree, reducing risk, inhibiting cancer, treating drug-resistant tumour or tumours or destruction of cancer cells. Said cancer is selected from a group consisting of prostate cancer, breast cancer, ovarian cancer, skin cancer, melanoma, metastatic melanoma, lung cancer, colon cancer, leukaemia, kidney cancer, CNS cancer and combinations thereof. Said tumour is selected from a group Consisting melanoma tumour, tumour metastatic melanoma, tumor of prostate cancer and ovarian tumour.EFFECT: technical result is compounds with anticancer activity.12 cl, 38 dwg, 33 tbl, 30 ex

Process for preparation of pemetrexed and lysin salt thereof // 2609006
FIELD: chemistry.SUBSTANCE: invention relates to a method of producing pemetrexed salt, having general formula I, where B+ denotes Na+ or protonated lysine, and having anticancer activity. Method includes following stages: a) reaction of 4-(2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo(2,3-d)pyrimidin-5-yl)ethyl)benzoic acid (2) with diethyl-L-glutamate hydrochloride in presence of a binding agent to produce pemetrexed diethyl ester (3); b) hydrolysis of pemetrexed diethyl ester (3) to pemetrexed acid (5); c) forming salts with a base selected from NaOH or lysine, to produce corresponding pemetrexed salt. Method is characterized by that, that at step a) acid (2) is pre-converted in situ into corresponding sodium carboxylate or morpholine carboxylate, which can be separated or directly react, wherein used reaction solvent consists of water-alcohol mixture of solvents, where alcohol is selected from methanol, ethanol, isopropanol and n-propanol, and an intermediate compound of pemetrexed diethyl ester (3) is directly precipitated from reaction mixture with purity >98 %. Invention also relates to a (bi)lysine salt of N-[4-[2-(2-amino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid (pemetrexed) of formula (1), which is more stable, synthesis method thereof and a pharmaceutical composition containing said salt.EFFECT: method enables to directly precipitate intermediate pemetrexed diethyl ester into a reaction mixture, obtaining said ester with high purity.15 cl, 9 dwg, 3 tbl, 20 ex
(alpha-substituted aralkylamino- and heteroarylalkylamino)pyrimidinyl- and 1,3,5-triazinylbenzimidazoles, pharmaceutical compositions thereof and use thereof in treating proliferative diseases // 2608742
FIELD: chemistry.SUBSTANCE: present invention relates to novel compounds of formula I, , having PI3K enzymatic activity.EFFECT: novel compounds of formula I are obtained, which can be used for regulation of PI3K enzymatic activity, as well as pharmaceutical compositions based thereon.33 cl, 2 tbl, 63 ex, 3 sch

Anti c-met receptor protein antibodies // 2608644
FIELD: biochemistry.SUBSTANCE: invention relates to biochemistry. Described is an antibody or its antigen-binding fragment which specifically binds to human c-Met protein. Also described is an isolated polynucleotide coding said antibody, an expression vector containing said polynucleotide, a host cell containing said vector. Disclosed is a method of producing a recombinant antibody by culturing described host cell. Disclosed is a pharmaceutical composition for treating cancer and an immunoconjugate containing described antibody. Disclosed is a method of treating cancer involving administering described antibody.EFFECT: invention widens range of agents for treating cancer.15 cl, 25 dwg, 16 tbl, 26 ex

Adamantane-containing indoles and their hydrochlorides with microtubules stabilizing property, methods of their production, pharmacological agent based thereon and method of treating and preventing diseases associated with microtubule system disorders // 2608631
FIELD: chemistry; medicine.SUBSTANCE: invention relates to novel adamantane-containing indoles and their hydrochlorides of general formula 1, in which R1, R2, R3, R4 can be identical or different and independently represent H, F, Cl, Br, (C1-C6)alkyl, (C1-C6)alkoxy; R5, R6 can be identical or different and independently represent H, (C1-C6)alkyl, ONO2; X is CH2CH(OH)CH2 or CH2CH2C(O); Z = no, Cl; R7, R8, R9, R10 can be identical or different and independently represent H, F, Cl, Br, (C1-C6)alkyl, (C1-C6)alkoxy; R11, R12, R13, R14, R15, R16, R17, R18 can be identical or different and independently represents H, (C1-C6)alkyl.EFFECT: compounds possess microtubules stabilization property and may be used for treating or preventing diseases related to disturbed microtubule system, for example, such as hyperproliferative manifestations and neurodegenerative disorders.22 cl, 7 dwg, 54 ex ,
ethod of prediction of recurrent vulvar cancer i and ii stage // 2608508
FIELD: medicine.SUBSTANCE: invention relates to medicine and concerns a method for prediction of relapse vulvar I and II stage. Proposed method consists in determining in tumour tissue a DNA of human papilloma virus by method of polymerase chain reaction. In the patients with stage I disease in the presence of virus, predict relapse by 57.3±0.3 months, in the absence of virus – through 36±0.12 months, in the patients with II stage of disease in the presence of virus occurrence of relapse is predicted through 48±0.2 months, while the absence of virus – through 27.1±0.08 months.EFFECT: invention can be used in gynecology for prediction of recurrent carcinoma of vulva.1 cl, 1 tbl, 4 ex
 
2551082.
Up!